ReviewCurrent opinion in immunology2026
Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy.
Review in Current opinion in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Allogeneic hematopoietic cell transplantation (alloHCT) is curative for many patients with high-risk, hematologic malignancies. AlloHCT depends on a graft versus malignancy (GVM) phenomenon, whereby donor-derived immune cells recognize and eradicate malignant host cells. Successful GVM correlates with the risk of alloreactivity against healthy tissues (graft-vs-host disease [GVHD]). HLA genes are central to immunologic recognition of self and mediate both GVM and GVHD. Historically, HLA-mismatched alloHCT was limited by the high incidence of severe GVHD. This led to a strong preference for HLA-matched donors, limiting access to HCT in patients without an HLA-matched donor. More recent advances in the prevention of GVHD, such as post-transplant cyclophosphamide, resulted in improved outcomes after HLA-mismatched donor HCT. New possibilities now exist to select donors for strategies designed to exploit GVM without significant GVHD. Here, we discuss the practical applications of donor selection to improve the overall efficacy of alloHCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.